Clarivate | Jotup

Clarivate Reports First Quarter 2024 Results

Retrieved on:

星期三, 五月 8, 2024

Webcast, Bank statement, ID, Clarivate, GAAP, EPS, Interest

LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.

Key Points:

(2) Adjusted diluted EPS for 2024 is calculated based on approximately 730 million fully diluted weighted average ordinary shares outstanding.
Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time.
As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.
Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results.

Clarivate Reports First Quarter 2024 Results

Retrieved on:

星期三, 五月 8, 2024

Webcast, Bank statement, ID, Clarivate, GAAP, EPS, Interest

LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.

Key Points:

(2) Adjusted diluted EPS for 2024 is calculated based on approximately 730 million fully diluted weighted average ordinary shares outstanding.
Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time.
As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.
Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results.

Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

Retrieved on:

星期二, 五月 7, 2024

Epidemiology, Intelligence, Forecasting, CLVT, Incidence, Patient, Clarivate, Prevalence

LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.

Key Points:

Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™ .
It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population.
Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform.

Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis

Retrieved on:

星期二, 五月 7, 2024

Epidemiology, Intelligence, Forecasting, CLVT, Incidence, Patient, Clarivate, Prevalence

LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.

Key Points:

Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™ .
It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population.
Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform.

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success

Retrieved on:

星期四, 五月 2, 2024

Intelligence, Product management, Health care, CLVT, Patient, Clarivate, CMC, Mobile phone

LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.

Key Points:

LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence ™ solution, featuring a new post-approval variations module.
The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.
Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.
With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics.

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success

Retrieved on:

星期四, 五月 2, 2024

Intelligence, Product management, Health care, CLVT, Patient, Clarivate, CMC, Mobile phone

LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.

Key Points:

LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence ™ solution, featuring a new post-approval variations module.
The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.
Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.
With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics.

Clarivate joins United Nations SDG Publishers Compact

Retrieved on:

星期三, 四月 24, 2024

LONDON, April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.

Key Points:

LONDON, April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.
Liliana Hinderman, Senior Vice President, Chief Risk and Sustainability Officer said: "We have signed the UN SDG Publishers Compact as a commitment to thinking forward to grow our global impact on SDGs worldwide.
SDG 9: Industry, innovation and infrastructure: Clarivate data and insights support customers along the innovation lifecycle, bringing innovations to market faster.
Clarivate is part of the global community of business leaders who are signatories to the United Nations Global Compact, United Nations Women's Empowerment Principles, CEO Action on Diversity and Inclusion, the Stonewall Transgender Rights are Human Rights campaign and Science-Based Targets initiative.

Clarivate joins United Nations SDG Publishers Compact

Retrieved on:

星期三, 四月 24, 2024

LONDON, April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.

Key Points:

LONDON, April 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces it has signed the United Nations Sustainable Development Goals (UN SDGs) Publishers Compact.
Liliana Hinderman, Senior Vice President, Chief Risk and Sustainability Officer said: "We have signed the UN SDG Publishers Compact as a commitment to thinking forward to grow our global impact on SDGs worldwide.
SDG 9: Industry, innovation and infrastructure: Clarivate data and insights support customers along the innovation lifecycle, bringing innovations to market faster.
Clarivate is part of the global community of business leaders who are signatories to the United Nations Global Compact, United Nations Women's Empowerment Principles, CEO Action on Diversity and Inclusion, the Stonewall Transgender Rights are Human Rights campaign and Science-Based Targets initiative.

Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets

Retrieved on:

星期二, 四月 23, 2024

DRG, CLVT, IP, Clarivate, Decision, Health care, ProQuest, Workflow, Medtech, Software as a service, API, Intelligence, Automation, Patient, Acquisition, Active ingredient, Medical device

LONDON, April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed.

Key Points:

Clarivate brings together connected data, deep expertise and intelligence solutions to empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster.
The workflow and reporting capabilities of Global Q complement the Clarivate Cortellis Generics Intelligence solution for Active Pharmaceutical Ingredient (API) tracking.
The addition of these cloud-based solutions will serve to embed Clarivate into critical client workflows and enable the expansion of Clarivate services into new markets.
Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "Clarivate continues to explore, develop and integrate next-generation workflow automation software that streamlines and digitizes manual workflows.

Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets

Retrieved on:

星期二, 四月 23, 2024

DRG, CLVT, IP, Clarivate, Decision, Health care, ProQuest, Workflow, Medtech, Software as a service, API, Intelligence, Automation, Patient, Acquisition, Active ingredient, Medical device

LONDON, April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed.

Key Points:

Clarivate brings together connected data, deep expertise and intelligence solutions to empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster.
The workflow and reporting capabilities of Global Q complement the Clarivate Cortellis Generics Intelligence solution for Active Pharmaceutical Ingredient (API) tracking.
The addition of these cloud-based solutions will serve to embed Clarivate into critical client workflows and enable the expansion of Clarivate services into new markets.
Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "Clarivate continues to explore, develop and integrate next-generation workflow automation software that streamlines and digitizes manual workflows.